| Description |
Multiple variants of SARS-CoV-2 are circulating globally and posting new challenges to human health. As concerns over the potential impacts of the variants grow, people ask if one possesses protective neutralizing antibodies (NAbs) against the variants after receiving the currently available vaccines; and if the NAb therapeutic agents are equally effective to treat the mutant infection as the wild type. To facilitate the mutant-related research, drug trials and vaccine assessments, a high-throughput assay to measure neutralizing antibodies against the mutants is in urgent need. |
検索
お問い合わせリスト